Key result
Nebivolol effectively lowers blood pressure in mild to moderate hypertension via increased nitric oxide release.
Why the study?
There are controversies regarding the use of beta blockers as initial therapy for arterial hypertension based on different treatment guidelines.
Is nebivolol an effective and well-tolerated treatment for mild to moderate arterial hypertension?
Is nebivolol an effective and well-tolerated treatment for mild to moderate arterial hypertension?
Nebivolol is a third-generation beta-blocker with unique vasodilatory properties via nitric oxide release, offering a favorable metabolic and hemodynamic profile for hypertension management.
May support nebivolol in mild-moderate hypertension; extends NO-vasodilation data but leaves comparative efficacy open.
Beta blockers are one of the classes of antihypertensive drugs, but there are controversies of their use as an initial therapy in treatment of arterial hypertension based on different guidelines for treatment of arterial hypertension.Nebivolol is a third generation, highly selective β-adrenoceptor antagonist with antihypertensive efficacy similar to other beta blockers but with unique function of increasing the release of nitric oxide (NO) via activation of β3-adrenergic receptors which improves endothelial function, produces vasodilatation, improves arterial compliance and reduces peripheral vascular resistance.Nebivolol highly selective lipophilic B1-adrenergic receptor antagonist and B3 agonist has different pharmacokinetics and pharmacodynamics profile from other beta blockers with more favourable metabolic and hemodynamic profile, like side effect profile, beta receptors blockade affinity, vasodilating properties, and improvement of endothelial function.Nebivolol has been show to be effective beta blocker for treatment of mild to moderate arterial hypertension as monotherapy or in combination therapy.
No takes yet. Share an insight, caveat, or question.
A 2016 study conducted a review in Arterial hypertension. Nebivolol was evaluated. Nebivolol is a third-generation beta-blocker that effectively treats mild to moderate hypertension by increasing nitric oxide release, offering a favorable hemodynamic and metabolic profile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: